PhioPharmaceuticalsCorp . (PHIO) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of PhioPharmaceuticalsCorp . (NASDAQ:PHIO) from a hold rating to a buy rating in a research note released on Monday, April 1st, ValuEngine reports.

Shares of PhioPharmaceuticalsCorp . stock traded up $0.02 during trading on Monday, hitting $0.50. 239,691 shares of the company’s stock were exchanged, compared to its average volume of 619,545. PhioPharmaceuticalsCorp . has a 52-week low of $0.27 and a 52-week high of $2.84. The stock has a market cap of $11.04 million, a PE ratio of -0.48 and a beta of 2.05.

PhioPharmaceuticalsCorp . (NASDAQ:PHIO) last issued its earnings results on Wednesday, March 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. PhioPharmaceuticalsCorp . had a negative net margin of 4,990.20% and a negative return on equity of 153.67%. On average, analysts predict that PhioPharmaceuticalsCorp . will post -0.37 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in PhioPharmaceuticalsCorp . stock. Virtu Financial LLC bought a new stake in PhioPharmaceuticalsCorp . (NASDAQ:PHIO) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 238,544 shares of the company’s stock, valued at approximately $107,000. Virtu Financial LLC owned 1.07% of PhioPharmaceuticalsCorp . as of its most recent SEC filing. 9.86% of the stock is owned by hedge funds and other institutional investors.

PhioPharmaceuticalsCorp . Company Profile

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Further Reading: What Is An Exchange-Traded Fund (ETF)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for PhioPharmaceuticalsCorp . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhioPharmaceuticalsCorp . and related companies with MarketBeat.com's FREE daily email newsletter.